THE WOODLANDS, Texas--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NYSE MKT: PTX), a specialty pharmaceutical company, today announced that it has been approved for listing on the NASDAQ Global Market under the symbol “PTX.” Trading on the NASDAQ Global Market is expected to commence on January 28, 2013. The Company’s common stock will continue to trade on the NYSE MKT until the market close on January 25, 2013.
